<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03440060</url>
  </required_header>
  <id_info>
    <org_study_id>301401</org_study_id>
    <nct_id>NCT03440060</nct_id>
  </id_info>
  <brief_title>Procalcitonin-guided Antibiotic Therapy During Severe Acute Exacerbation of COPD</brief_title>
  <official_title>Procalcitonin-guided Antibiotic Therapy During Severe Acute Exacerbation of COPD Requiring Mechanical Ventilation: a Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Mahdia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Mahdia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assess whether a procalcitonin guided antibiotic therapy can reduce significantly
      unnecessary antibiotic prescription during severe exacerbation of COPD requiring mechanical
      ventilation without compromising patients' outcome. The first group of patients will receive
      systematically empiric antibiotic therapy and the second group will receive antibiotics only
      if procalcitonin value is at or greater than 0.25 ng/ml.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently, procalcitonin gained interest as the most reliable biomarker in predicting
      bacterial origin in low respiratory tract infections and sepsis.

      Procalcitonin was shown to be non-inferior to standard guidelines in guiding antibiotic
      therapy during COPD exacerbation, without worsening patients' outcomes, and with a
      significant reduction in antibiotic exposure.

      Its use to guide antibiotic treatment during COPD exacerbation may be more challenging
      because of the frequent colonization of the airways in patients with COPD, and thus it needs
      further evaluation.

      Additionally, until today, no interventional studies evaluating procalcitonin protocol have
      been conducted in ventilated COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to recovery</measure>
    <time_frame>28 days</time_frame>
    <description>defined by resolution of symptoms ( cough, sputum purulence and respiratory rate less than 25 breath per minute) and NIV withdrawal (normal pH for 24 consecutive hours after stopping NIV), for patients with home NIV investigators retain stabilization after returning to the same number of hours of NIV before current exacerbation and pH normalization for 24 consecutive hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic exposure at day 90</measure>
    <time_frame>90 days</time_frame>
    <description>number of days the patient received antibiotics for any infection within 90 days from the day of admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmission for another exacerbation at day 90</measure>
    <time_frame>90 days</time_frame>
    <description>another readmission for another episode of COPD exacerbation within 90 days after a first discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIV failure</measure>
    <time_frame>28 days</time_frame>
    <description>clinical deterioration requiring invasive ventilation or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of say (days)</measure>
    <time_frame>90 days</time_frame>
    <description>number of days spent in the ICU during the index exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay (days)</measure>
    <time_frame>90 days</time_frame>
    <description>number of days spent in hospital during the index exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Exacerbation Copd</condition>
  <arm_group>
    <arm_group_label>standard group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>participants receive systematically empiric antibiotic therapy on admission with amoxicillin- acid clavulanic or levofloxacin in case of allergy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Procalcitonin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>participants receive antibiotics only if the procalcitonin value is at or greater than 0.25 ng/ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>procalcitonin</intervention_name>
    <description>procalcitonin value will be obtained within 24 hours after ICU admission in both groups and will be taken into account in the procalcitonin group only</description>
    <arm_group_label>Procalcitonin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt; 40 years old who consent to the study protocol

          -  COPD diagnosis based on GOLD guidelines

        Exclusion Criteria:

          -  Patients who did not consent

          -  Asthma

          -  Malignancy

          -  Immunocompromised

          -  Survival for at least 1 year is unlikely

          -  Patients already enrolled in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tilouche Nejla</name>
      <address>
        <city>Mahdia</city>
        <zip>5100</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nejla Tilouche, MD</last_name>
      <phone>0021623277911</phone>
      <email>tilouche.nejla@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <reference>
    <citation>Mathioudakis AG, Chatzimavridou-Grigoriadou V, Corlateanu A, Vestbo J. Procalcitonin to guide antibiotic administration in COPD exacerbations: a meta-analysis. Eur Respir Rev. 2017 Jan 31;26(143). pii: 160073. doi: 10.1183/16000617.0073-2016. Print 2017 Jan. Review.</citation>
    <PMID>28143877</PMID>
  </reference>
  <results_reference>
    <citation>Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, MÃ¼ller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7.</citation>
    <PMID>14987884</PMID>
  </results_reference>
  <results_reference>
    <citation>Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B; ProHOSP Study Group. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009 Sep 9;302(10):1059-66. doi: 10.1001/jama.2009.1297.</citation>
    <PMID>19738090</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Mahdia</investigator_affiliation>
    <investigator_full_name>Nejla Tilouche</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>procalcitonin</keyword>
  <keyword>mechanical ventilation</keyword>
  <keyword>COPD exacerbation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

